as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,184.9
Change
-17.9 (-1.49%)
Open
₹1,202.8
Prev. Close
₹1,202.8
Day High
₹1,209.6
Day Low
₹1,177.2
Volume Analysis
Traded
143,012
Delivered
78,414
Delivery %
54.83%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong return on equity (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,236.34 | ₹1,222.97 | ₹1,203.94 | ₹1,190.57 | ₹1,171.54 | ₹1,158.17 | ₹1,139.14 |
| Fibonacci | ₹1,222.97 | ₹1,210.59 | ₹1,202.95 | ₹1,190.57 | ₹1,178.19 | ₹1,170.55 | ₹1,158.17 |
| Camarilla | ₹1,193.81 | ₹1,190.84 | ₹1,187.87 | ₹1,190.57 | ₹1,181.93 | ₹1,178.96 | ₹1,175.99 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+30.02%
1 Week
-4.06%
1 Month
+16.18%
3 Months
+8.42%
6 Months
+22.97%
1 Year
+45.3%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹676.41
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.7%
Net margin 12.67% × asset turnover 0.71x × equity multiplier 2.19x
Company Overview
Sector
Healthcare
Market Cap
₹10,922 Cr
P/E (TTM)
18.8
ROE
20.0%
Book Value
₹337.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Strides Pharma Sci Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Momentum (85/100), while Corporate Governance (50/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.0%). FII holding has been rising.
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 20.1% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%
- −Stock is trading at 3.51 times its book value
- −The company has delivered a poor sales growth of 7.94% over past five years.
- −Promoters have pledged 38.1% of their holding.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Trading window closed from October 1, 2026 until 48 hours after Q2 FY27 results.
Strides submits FY26 Sustainability Report aligned with GRI 2021, SASB, UNGC and SDG mappings.
USFDA completed cGMP inspection at Alathur facility; issued Form 483 with three observations.
Strides receives USFDA EIR for Bengaluru flagship facility after VAI inspection closure.
Strides Pharma held 35th AGM on Aug 14, 2026; shareholders approved dividend and director appointments.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 930 | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 |
| Expenses + | 796 | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 |
| Operating Profit | 134 | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 |
| OPM % | 14.0% | 11.0% | 13.0% | 16.0% | 18.0% | 16.0% | 18.0% | 18.0% | 19.0% | 19.0% | 20.0% | 18.0% | 18.0% |
| Other Income + | 3 | -129 | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 |
| Interest | 76 | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 |
| Depreciation | 60 | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 |
| Profit before tax | 0 | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 |
| Tax % | 3,025.0% | -5.0% | 23.0% | 55.0% | 1.0% | 16.0% | 21.0% | 20.0% | 13.0% | 14.0% | 15.0% | 13.0% | 17.0% |
| Net Profit + | -9 | -149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 |
| EPS in Rs | -1 | -15 | 5 | 2 | 365 | 8 | 10 | 9 | 11 | 14 | 22 | 14 | 17 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,004 |
| Expenses + | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,338 | 2,779 | 3,201 | 3,544 | 3,362 | 3,763 | 3,933 | 4,070 |
| Operating Profit | 229 | 374 | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 | 935 |
| OPM % | 19.0% | 13.0% | 19.0% | 14.0% | 9.0% | 15.0% | 16.0% | -4.3% | 3.9% | 14.0% | 18.0% | 19.0% | 19.0% |
| Other Income + | 874 | 63 | 291 | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3,313 | 124 | 193 |
| Interest | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 | 172 |
| Depreciation | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 | 210 |
| Profit before tax | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3,675 | 669 | 746 |
| Tax % | 15.0% | 31.0% | 12.0% | 1.0% | -9.0% | 27.0% | 11.0% | -27.0% | -21.0% | 45.0% | 2.0% | 14.0% | — |
| Net Profit + | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 | 634 |
| EPS in Rs | 142 | 12 | 45 | 74 | 36 | 4 | 30 | -51 | -22 | -8 | 390 | 60 | 67 |
| Dividend Payout % | 76.0% | 41.0% | 10.0% | 3.0% | 8.0% | 345.0% | 8.0% | 0.0% | -7.0% | -33.0% | 1.0% | 8.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 | 3,015 |
| Borrowings + | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | 1,758 |
| Other Liabilities + | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | 1,941 |
| Total Liabilities | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
| Fixed Assets + | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | 2,101 |
| CWIP | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 447 |
| Investments | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 |
| Other Assets + | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | 3,967 |
| Total Assets | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 |
| Equity Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from Investing Activity + | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing Activity + | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| CFO/OP | 61 | 40 | 66 | 61 | 59 | 60 | 60 | 199 | -30 | 128 | 77 | 84 |
| Free Cash Flow | -157 | -293 | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 35.06% | 33.75% | 31.52% | 28.87% | 25.83% | 27.78% | 29.65% | 30.38% | 30.62% | 29.59% | 28.96% | 28.28% |
| Promoters | 27.79% | 27.39% | 25.88% | 25.86% | 25.84% | 26.82% | 28.3% | 28.3% | 27.86% | 27.86% | 27.91% | 27.91% |
| Government | 0.4% | 0.39% | 0.39% | 0.39% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 17.25% | 19.45% | 24.57% | 26.71% | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.4% |
| DII | 19.5% | 19.02% | 17.66% | 18.17% | 18.24% | 16.92% | 13.72% | 13.3% | 12.98% | 13.02% | 14.44% | 15.42% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Strides Pharma Sci Ltd (this stock) | 10,922 | 18.8 | 3.52 | 20.0% |
| Yatharth Hosp & Tra C S L | 10,899 | 60.2 | 6.1 | 10.4% |
| Blue Jet Healthcare Ltd | 11,040 | 78.3 | — | 52.1% |
| Viyash Scientific Limited | 10,791 | 48.7 | 3.66 | 7.39% |
| Healthcare Glob. Ent. Ltd | 10,558 | 219.0 | 7.93 | 2.54% |
| Metropolis Healthcare Ltd | 12,086 | 58.1 | 7.99 | 13.6% |
| Park Medi World Limited | 12,368 | 44.5 | 6.11 | 16.8% |
Which Mutual Funds Hold Strides Pharma Sci Ltd?
Frequently Asked Questions about Strides Pharma Sci Ltd
Strides Pharma Sci Ltd (STAR) closed at ₹1,184.9 on NSE on 25 September 2026, down 17.9 (1.49%) from the previous close.
Strides Pharma Sci Ltd trades on the NSE (National Stock Exchange of India) under the symbol STAR.
Strides Pharma Sci Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 18.8.
Strides Pharma Sci Ltd has a dividend yield of 0.42%.
Strides Pharma Sci Ltd's 52-week high is ₹1,261.0 and its 52-week low is ₹769.0.
Strides Pharma Sci Ltd has a market capitalisation of ₹10,922 crore.
Strides Pharma Sci Ltd has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Strides Pharma Sci Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.